Want to see GB:FUM full AI Analyst Report?

Futura Medical (FUM) Price & Analysis

55 Followers

FUM Stock Chart & Stats

1.23 p

-0.23 p(-0.73%)

At close: Jan 09 4:00 PM EST

1.23 p

-0.23 p(-0.73%)

Day’s Range― - ―

52-Week Range0.42 p - 15.00 p

Previous CloseN/A

Volume13.08K

Average Volume (3M)3.22M

Market Cap

£3.02M

Enterprise Value-1.60M

Total Cash (Recent Filing)£3.40M

Total Debt (Recent Filing)£0.00

Price to Earnings (P/E)―

Beta0.38

Next Earnings

Sep 22, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding581,327,760

10 Day Avg. Volume4,828,957

30 Day Avg. Volume3,220,377

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)1.30

Price to Sales (P/S)2.15

P/FCF Ratio-0.65

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)>-0.01

Revenue Forecast (FY)£5.10M

Bulls Say, Bears Say

Bulls Say

Financial PerformanceRevenues increased to £13.9m, ahead of market expectations and up 349% vs. FY23 (£3.1m).

Product DevelopmentFutura's female sexual dysfunction product, WSD4000, has delivered positive results in a home user study, which saw the product deliver an overall positive change in sexual function after four weeks.

Product LaunchThe year saw the business achieve several key milestones including the launch of Eroxon in the US (via partner Haleon) alongside over 15 countries across the Americas, Middle East and Europe.

Bears Say

Market OutlookInvestors will rightly be focused on 2025 and outlook following the trading update on Jan 30 flagging slower-than-expected initial consumer uptake in the US and slower-than-planned EU market roll-outs.

Revenue ForecastFutura has reiterated that it expects FY25 revenues to be approx. 50% lower than previously expected.

Futura Medical News

Futura Medical Posts Strong WSD4000 Trial Data as It Targets Underserved Female Sexual Health Market

An update from Futura Medical ( ($GB:FUM) ) is now available. Futura Medical has reported highly positive results...

2d ago

Futura Medical Wins Shareholder Backing for All AGM Resolutions

The latest update is out from Futura Medical ( ($GB:FUM) ). Futura Medical reported that shareholders approved all...

3d ago

Futura Medical Wins Strong Shareholder Backing at AGM

Futura Medical ( ($GB:FUM) ) just unveiled an announcement. Futura Medical said shareholders approved all resolutions at its...

3d ago

Futura pivots U.S. Eroxon strategy with new MPG distribution deal

The latest update is out from Futura Medical ( ($GB:FUM) ). Futura Medical has terminated its underperforming U.S....

3d ago

Futura Medical Sets June AGM and Publishes 2025 Annual Report

Futura Medical ( ($GB:FUM) ) just unveiled an update. Futura Medical has scheduled its Annual General Meeting for...

28d ago

Futura Medical Updates Market on Block Listing and Share Option Balances

The latest announcement is out from Futura Medical ( ($GB:FUM) ). Futura Medical has reported its latest six-monthly...

1M ago

Futura Medical Swings to Loss as Eroxon Sales Lag and Cash Runway Tightens

Futura Medical ( ($GB:FUM) ) has shared an update. Futura Medical reported a sharp deterioration in 2025 results,...

2M ago

Futura Medical Sets Date for 2025 Results and Investor Webinar as Sexual Health Portfolio Expands

Futura Medical ( ($GB:FUM) ) just unveiled an update. Futura Medical, the AIM-listed consumer healthcare group best known...

2M ago

Futura Medical Sets Date for 2025 Results and Investor Webinar

Futura Medical ( ($GB:FUM) ) has provided an update. Futura Medical will publish its full-year results for 2025...

2M ago

Futura Medical Reports Positive Home User Data for Eroxon and New Intense Formula

An announcement from Futura Medical ( ($GB:FUM) ) is now available. Futura Medical reported positive results from a...

3M ago

FUM FAQ

What was Futura Medical PLC’s price range in the past 12 months?

Futura Medical PLC lowest share price was 0.42 p and its highest was 15.00 p in the past 12 months.

What is Futura Medical PLC’s market cap?

Futura Medical PLC’s market cap is £3.02M.

When is Futura Medical PLC’s upcoming earnings report date?

Futura Medical PLC’s upcoming earnings report date is Sep 22, 2026 which is in 82 days.

How were Futura Medical PLC’s earnings last quarter?

Futura Medical PLC released its earnings results on Apr 29, 2026. The company reported -0.006 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.006 p.

Is Futura Medical PLC overvalued?

According to Wall Street analysts Futura Medical PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Futura Medical PLC pay dividends?

Futura Medical PLC does not currently pay dividends.

What is Futura Medical PLC’s EPS estimate?

Futura Medical PLC’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Futura Medical PLC have?

Futura Medical PLC has 581,327,760 shares outstanding.

What happened to Futura Medical PLC’s price movement after its last earnings report?

Futura Medical PLC reported an EPS of -0.006 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -31.538%.

Which hedge fund is a major shareholder of Futura Medical PLC?

Currently, no hedge funds are holding shares in GB:FUM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Futura Medical PLC

Futura Medical plc operates as a pharmaceutical firm specializing in the creation and advancement of consumer healthcare products. The company primarily targets the sexual health and pain management sectors. Its leading innovation is MED3000, a topical gel specifically formulated to treat erectile dysfunction. Additionally, Futura Medical offers a variety of pain relief solutions, including TPR100, a topical diclofenac gel; CBD100, a cannabidiol-based topical application; and TIB200, an ibuprofen topical gel. Established in 2001, the company is headquartered in Guildford, United Kingdom.